CL2008002273A1 - Uso de un compuesto capaz de aumentar el flujo de iones a traves de los canales de potasio kcnq, util para reducir los sintomas de, o para tratar trastornos en los cuales el sistema dopaminergico esta perturbado, como esquizofrenia y otros estados psicoticos. - Google Patents

Uso de un compuesto capaz de aumentar el flujo de iones a traves de los canales de potasio kcnq, util para reducir los sintomas de, o para tratar trastornos en los cuales el sistema dopaminergico esta perturbado, como esquizofrenia y otros estados psicoticos.

Info

Publication number
CL2008002273A1
CL2008002273A1 CL2008002273A CL2008002273A CL2008002273A1 CL 2008002273 A1 CL2008002273 A1 CL 2008002273A1 CL 2008002273 A CL2008002273 A CL 2008002273A CL 2008002273 A CL2008002273 A CL 2008002273A CL 2008002273 A1 CL2008002273 A1 CL 2008002273A1
Authority
CL
Chile
Prior art keywords
schizophrenia
disturbed
useful
compound capable
symptoms
Prior art date
Application number
CL2008002273A
Other languages
English (en)
Spanish (es)
Inventor
Henriette Husum Bak-Jensen
Klaus Peter Hertel
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39810209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002273(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2008002273A1 publication Critical patent/CL2008002273A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2008002273A 2007-08-01 2008-08-01 Uso de un compuesto capaz de aumentar el flujo de iones a traves de los canales de potasio kcnq, util para reducir los sintomas de, o para tratar trastornos en los cuales el sistema dopaminergico esta perturbado, como esquizofrenia y otros estados psicoticos. CL2008002273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200701110 2007-08-01

Publications (1)

Publication Number Publication Date
CL2008002273A1 true CL2008002273A1 (es) 2009-07-17

Family

ID=39810209

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002273A CL2008002273A1 (es) 2007-08-01 2008-08-01 Uso de un compuesto capaz de aumentar el flujo de iones a traves de los canales de potasio kcnq, util para reducir los sintomas de, o para tratar trastornos en los cuales el sistema dopaminergico esta perturbado, como esquizofrenia y otros estados psicoticos.

Country Status (17)

Country Link
US (1) US20100256145A1 (https=)
EP (1) EP2185149A1 (https=)
JP (1) JP2011513196A (https=)
KR (1) KR20100050502A (https=)
CN (1) CN101790374A (https=)
AR (1) AR070513A1 (https=)
AU (1) AU2008281112A1 (https=)
BR (1) BRPI0814180A2 (https=)
CA (1) CA2694887A1 (https=)
CL (1) CL2008002273A1 (https=)
EA (1) EA201070189A1 (https=)
MX (1) MX2010001171A (https=)
NZ (1) NZ582942A (https=)
TW (1) TW200920350A (https=)
UA (1) UA97847C2 (https=)
WO (1) WO2009015667A1 (https=)
ZA (1) ZA201000129B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
KR101563383B1 (ko) * 2008-02-21 2015-10-26 미쓰비시 타나베 파마 코퍼레이션 경구 투여용 고형 제제
PL2317852T3 (pl) 2008-07-16 2015-05-29 Richter Gedeon Nyrt Preparaty farmaceutyczne zawierające ligandy receptora dopaminy
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
WO2010105189A1 (en) * 2009-03-12 2010-09-16 The Johns Hopkins University Method for identifying compounds that attenuate the function or reduce abundance of a voltage-gated potassium channel and are associated with maintenance of cognitive function in old age
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
EP2408747A1 (en) 2009-03-17 2012-01-25 NeuroSearch A/S Substituted pyridine derivatives and their medical use
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
MX2011012743A (es) * 2009-05-29 2012-04-20 Astellas Pharma Inc Nueva composicion farmaceutica para la prevencion y/0 tratamiento del trastorno por deficit de atencion/hiperactividad.
WO2011133661A2 (en) 2010-04-21 2011-10-27 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
CA2804165C (en) 2010-07-08 2015-02-24 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2844247A4 (en) * 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN103012381B (zh) * 2013-01-10 2015-01-07 山东大学 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
EP3076968B1 (en) * 2013-12-02 2019-04-17 ChemoCentryx, Inc. Ccr6 compounds
CA2965467A1 (en) 2014-10-24 2016-04-28 Ono Pharmaceutical Co., Ltd. Kcnq2-5 channel activator
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
KR20190008411A (ko) 2016-06-10 2019-01-23 사이플루어 라이프 사이언시즈, 인크 플로오르화 2-아미노-4-(치환된 아미노)페닐 카르밤산염 유도체
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
HRP20230808T1 (hr) 2018-02-20 2023-11-10 H. Lundbeck A/S Derivati alkohola kao otvarači kv7 kalijevih kanala
TWI788325B (zh) * 2018-02-21 2023-01-01 丹麥商Ｈ 朗德貝克公司 作為Ｋｖ７鉀通道開放劑的醇衍生物
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
CN110511220B (zh) * 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN108707087B (zh) * 2018-06-29 2020-10-16 河北医科大学 一种4-(对三氟甲基苄基)-3-氟-1,2,4三苯胺衍生物及其药物组合物与用途
CN108863893A (zh) * 2018-07-09 2018-11-23 湖南博隽生物医药有限公司 二氢吲哚类衍生物及其在药物中的应用
EP3911647B1 (en) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
AU2020325517B2 (en) 2019-08-02 2025-08-28 H. Lundbeck A/S Alcohol derivatives as KV7 potassium channel openers
CN114206328B (zh) 2019-08-02 2024-09-17 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物
AR119521A1 (es) 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
WO2021092439A1 (en) 2019-11-08 2021-05-14 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
KR102643653B1 (ko) * 2020-11-13 2024-03-06 기초과학연구원 신규한 아미노방향족 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물
IL304920A (en) * 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用
WO2024099269A1 (zh) * 2022-11-11 2024-05-16 华东师范大学 芳基酰胺化合物、包含其的药物组合物及其用途
AU2024325576A1 (en) * 2023-08-17 2026-02-19 Xenon Pharmaceuticals Inc. Azepane and pyrrolidine compounds and uses thereof
CN121318764A (zh) * 2024-07-10 2026-01-13 宜昌人福药业有限责任公司 通道小分子激活剂及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172468B (https=) * 1990-07-14 1993-08-14 Asta Medica Ag
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
NZ516610A (en) * 1999-08-04 2004-05-28 Icagen Inc Benzanilides as potassium channel openers
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
CA2438868A1 (en) * 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
JP2004535413A (ja) * 2001-05-31 2004-11-25 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャンネルモジュレーターとしてのシンナミド誘導体
AU2003294442A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
MXPA05006463A (es) * 2002-12-27 2005-08-26 Lundbeck & Co As H Derivados de 1,2,4-triaminobenceno, utiles para tratar transtornos del sistema nervioso central.
EP1603858A2 (en) * 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
WO2004080950A1 (en) * 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
BRPI0408437A (pt) * 2003-03-21 2006-04-04 Lundbeck & Co As H derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma
EP1631546A1 (en) * 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
TWI357901B (en) * 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
EP1861394A1 (en) * 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives
EP1937653A1 (en) * 2005-09-09 2008-07-02 H.Lundbeck A/S Pyrimidine derivatives and their use as kcnq potassium channels openers
AU2007214128B2 (en) * 2006-02-07 2012-05-17 H. Lundbeck A/S Use of KCNQ-openers for treating or reducing the symptoms of schizophrenia
EP2012769A1 (en) * 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms

Also Published As

Publication number Publication date
CA2694887A1 (en) 2009-02-05
JP2011513196A (ja) 2011-04-28
MX2010001171A (es) 2010-03-01
EA201070189A1 (ru) 2010-08-30
KR20100050502A (ko) 2010-05-13
TW200920350A (en) 2009-05-16
EP2185149A1 (en) 2010-05-19
ZA201000129B (en) 2011-04-28
BRPI0814180A2 (pt) 2015-01-27
US20100256145A1 (en) 2010-10-07
UA97847C2 (ru) 2012-03-26
AR070513A1 (es) 2010-04-14
CN101790374A (zh) 2010-07-28
WO2009015667A1 (en) 2009-02-05
NZ582942A (en) 2011-09-30
AU2008281112A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
CL2008002273A1 (es) Uso de un compuesto capaz de aumentar el flujo de iones a traves de los canales de potasio kcnq, util para reducir los sintomas de, o para tratar trastornos en los cuales el sistema dopaminergico esta perturbado, como esquizofrenia y otros estados psicoticos.
CL2007001670A1 (es) Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas.
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
CY1121899T1 (el) Βοριουχα μικρομορια ως αντιφλεγμονωδεις παραγοντες
AR064301A1 (es) Absorbente de fosfato basado en hierro (iii)
UY30978A1 (es) Inhibidores de canales de iones
PH12013501558A1 (en) New compounds
CR11123A (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacteriales
HN2011002095A (es) [1,2,4] triazolo [1,5-a] pridinas como inhibidores de cinasa.
CL2012003602A1 (es) Compuestos heterociclicos nitrogenados fusionados, moduladores de fosfodiesterasas; un medicamento; un método para prevenir o tratar la esquizofrenia; y su uso para la produccion de un agente para prevenir o tratar la esquizofrenia.
ECSP10010025A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
ATE553104T1 (de) Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
DOP2010000078A (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3
DOP2007000107A (es) Nitrilos espirocíclicos como inhibidores de proteasa
AR059319A1 (es) Metodo para tratar o reducir los sintomas de la esquizofrenia
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
CL2008002185A1 (es) Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades.
EA201000258A1 (ru) Новые гербициды
CL2008002826A1 (es) Compuestos derivados de pirimidina alquiltio sustituidas, antagonista crth2; composicion farmaceutica que comprende a dicho compuestos; y uso para tratar una enfermedad alergica, asma, dermatitis atopica, psoriasis, colitis ulcerantes, sinusitis, leucemia basofilica, entre otras.
JO2978B1 (en) MGLU2 aids
CL2007000773A1 (es) Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.
BRPI0711885A2 (pt) Aminotiazóis e seus usos
EA201000069A1 (ru) Новые гербициды